CO2024007225A2 - Tratamiento de trastornos hepáticos con un agonista del thr-β - Google Patents

Tratamiento de trastornos hepáticos con un agonista del thr-β

Info

Publication number
CO2024007225A2
CO2024007225A2 CONC2024/0007225A CO2024007225A CO2024007225A2 CO 2024007225 A2 CO2024007225 A2 CO 2024007225A2 CO 2024007225 A CO2024007225 A CO 2024007225A CO 2024007225 A2 CO2024007225 A2 CO 2024007225A2
Authority
CO
Colombia
Prior art keywords
thr
agonist
treatment
liver disorders
disorders
Prior art date
Application number
CONC2024/0007225A
Other languages
English (en)
Spanish (es)
Inventor
Christopher T Jones
Sheng Guo
Matt Duan
Jianwei Bian
Kevin Klucher
D Barry Crittenden
Erin K Quirk
Feng Jin
Qianqian Dong
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of CO2024007225A2 publication Critical patent/CO2024007225A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
CONC2024/0007225A 2021-11-11 2024-06-07 Tratamiento de trastornos hepáticos con un agonista del thr-β CO2024007225A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021130083 2021-11-11
CN2022097426 2022-06-07
PCT/CN2022/131297 WO2023083288A1 (en) 2021-11-11 2022-11-11 TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST

Publications (1)

Publication Number Publication Date
CO2024007225A2 true CO2024007225A2 (es) 2024-10-31

Family

ID=86335128

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0007225A CO2024007225A2 (es) 2021-11-11 2024-06-07 Tratamiento de trastornos hepáticos con un agonista del thr-β

Country Status (14)

Country Link
US (1) US20240293416A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429666A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024544538A (cg-RX-API-DMAC7.html)
KR (1) KR20240101642A (cg-RX-API-DMAC7.html)
CN (1) CN118871113A (cg-RX-API-DMAC7.html)
AU (1) AU2022388507A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238108A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001399A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024007225A2 (cg-RX-API-DMAC7.html)
IL (1) IL312637A (cg-RX-API-DMAC7.html)
MX (1) MX2024005647A (cg-RX-API-DMAC7.html)
PE (1) PE20241327A1 (cg-RX-API-DMAC7.html)
TW (1) TW202332447A (cg-RX-API-DMAC7.html)
WO (1) WO2023083288A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2025245216A1 (en) * 2024-05-22 2025-11-27 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-beta agonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394463B (es) * 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
TW202615431A (zh) * 2018-07-02 2026-04-16 美商瑪德瑞高製藥公司 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式
CN121081472A (zh) * 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2021121210A1 (zh) * 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
WO2021231646A1 (en) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法

Also Published As

Publication number Publication date
CL2024001399A1 (es) 2024-11-08
CN118871113A (zh) 2024-10-29
TW202332447A (zh) 2023-08-16
WO2023083288A1 (en) 2023-05-19
CA3238108A1 (en) 2023-05-19
EP4429666A1 (en) 2024-09-18
PE20241327A1 (es) 2024-06-26
AU2022388507A1 (en) 2024-06-20
KR20240101642A (ko) 2024-07-02
JP2024544538A (ja) 2024-12-03
MX2024005647A (es) 2024-05-24
IL312637A (en) 2024-07-01
US20240293416A1 (en) 2024-09-05
EP4429666A4 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
CL2024001399A1 (es) Tratamiento de trastornos hepáticos con un agonista del thr-beta
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
BR112022023048A2 (pt) Tratamento de combinação de distúrbios hepáticos
CL2025002208A1 (es) Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas
CL2020000907A1 (es) Terapias de combinación y usos de las mismas.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
BR112021022363A2 (pt) Composições e métodos para fabricação de células t
PE20180260A1 (es) Metodos y kits para tratar la depresion
CO6290650A2 (es) Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
UY38721A (es) INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB
MX2022014237A (es) Tratamiento combinado de trastornos hepáticos.
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
CO2021002691A2 (es) Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1)
DOP2023000155A (es) Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
CO2024009144A2 (es) Inhibidores de cinasa met
MX2024012368A (es) Terapia combinada para el tratamiento del cancer
MX2022000441A (es) Metodos para tratar o prevenir la atrofia muscular espinal.
MX2021002761A (es) Metodos para tratar la pancreatitis.
CO2024001004A2 (es) Compuestos de sulfonimidamida y usos de los mismos
MX2022011845A (es) Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
MX2021011799A (es) Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa